|
LEVODOPA EFFECT IS REDUCED BY THE DRUG
|
CO-ADMINISTRATION WITH RANOLAZINE MAY INCREASE ITS PLASMA LEVELS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
ANTIPSYCHOTICS MAY ANTAGONISE THE ANTIEPILEPTIC ACTIVITY OF ANTIEPILEPTICS INCLUDING PHENOBARBITONE BY LOWERING THE CONVULSIVE THRESHOLD
|
ANTIPSYCHOTICS MAY ANTAGONISE THE ANTIEPILEPTIC ACTIVITY OF ANTIEPILEPTICS INCLUDING PHENOBARBITONE BY LOWERING THE CONVULSIVE THRESHOLD
|
ANTIPSYCHOTICS MAY ANTAGONISE THE ANTIEPILEPTIC ACTIVITY OF ANTIEPILEPTICS INCLUDING PHENOBARBITONE BY LOWERING THE CONVULSIVE THRESHOLD
|
ANTIPSYCHOTICS MAY ANTAGONISE THE ANTIEPILEPTIC ACTIVITY OF ANTIEPILEPTICS INCLUDING PHENOBARBITONE BY LOWERING THE CONVULSIVE THRESHOLD
|
ANTIPSYCHOTICS MAY ANTAGONISE THE ANTIEPILEPTIC ACTIVITY OF ANTIEPILEPTICS INCLUDING PHENOBARBITONE BY LOWERING THE CONVULSIVE THRESHOLD
|
ANTIPSYCHOTICS MAY ANTAGONISE THE ANTIEPILEPTIC ACTIVITY OF ANTIEPILEPTICS INCLUDING PHENOBARBITONE BY LOWERING THE CONVULSIVE THRESHOLD
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|
ATROPINE LIKE ANTICHOLENERGIC SIDE EFFECTS MAY POTENTIATE LEADING TO CENTRAL ANTICHILENERGIC SYNDROME
|